key: cord-0026462-d8ioopd5 authors: Su, Shu; Wong, William CW; Zou, Zhuoru; Cheng, Dan Dan; Ong, Jason J; Chan, Polin; Ji, Fanpu; Yuen, Man-Fung; Zhuang, Guihua; Seto, Wai-Kay; Zhang, Lei title: Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation date: 2022-01-18 journal: Lancet Glob Health DOI: 10.1016/s2214-109x(21)00517-9 sha: f13befa29a3d9a7cae155bb638eb85446f52e51e doc_id: 26462 cord_uid: d8ioopd5 BACKGROUND: China has the highest prevalence of hepatitis B virus (HBV) infection worldwide. Universal HBV screening might enable China to reach the WHO 2030 target of 90% diagnostics, 80% treatment, and 65% HBV-related death reduction, and eventually elimination of viral hepatitis. We evaluated the cost-effectiveness of implementing universal HBV screening in China and identified optimal screening strategies. METHODS: We used a Markov cohort model, inputting parameters based on data from previous studies and public databases, to assess the cost-effectiveness of four HBV serological screening strategies in China in different screening scenarios. We simulated universal screening scenarios in 15 adult age groups between 18 and 70 years, with different years of screening implementation (2021, 2026, and 2031) and compared to the status quo (ie, no universal screening); in total, we investigated 180 different screening scenarios. We calculated the incremental cost-effectiveness ratio (ICER) between the different screening strategies and the status quo (current screening strategy). We performed probabilistic and one-way deterministic sensitivity analyses to assess the robustness of our findings. FINDINGS: With a willingness-to-pay level of three times the Chinese gross domestic product (GDP) per capita (US$30 828), all universal screening scenarios in 2021 were cost-effective compared with the status quo. The serum HBsAg/HBsAb/HBeAg/HBeAb/HBcAb (five-test) screening strategy in people aged 18–70 years was the most cost-effective strategy in 2021 (ICER $18 295/quality-adjusted life-years [QALY] gained). This strategy remained the most cost-effective, when the willingness-to-pay threshold was reduced to 2 times GDP per capita. The two-test strategy for people aged 18–70 years became more cost-effective at lower willingness-to-pay levels. The five-test strategy could prevent 3·46 million liver-related deaths in China over the lifetime of the cohort. It remained the most cost-effective strategy when implementation was delayed until 2026 (ICER $20 183/QALY) and 2031 (ICER $23 123/QALY). Screening young people (18–30 years) will no longer be cost-effective in delayed scenarios. INTERPRETATION: The five-test universal screening strategy in people aged 18–70 years, implemented within the next 10 years, is the optimal HBV screening strategy for China. Other screening strategies could be cost-effective alternatives, if budget is limited in rural areas. Delaying strategy implementation reduces overall cost-effectiveness. Early screening initiation will aid global efforts in achieving viral hepatitis elimination. FUNDING: National Natural Science Foundation of China. are not reducible by more information. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence The cost effectiveness of hepatitis immunization for US college students Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation Economic evaluation of HBV vaccination: A systematic review of recent publications Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis. Archives of pediatrics & adolescent medicine Disease burden of chronic hepatitis B among immigrants in Canada Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection Cost-effectiveness analysis of neonatal hepatitis B immunization strategies in China Xi'an：Xi'an Jiaotong University Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B Economic evaluation of infant and adolescent hepatitis B vaccination in the UK Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis Large variations in risk of hepatocellular carcinoma and mortality in treatment naive hepatitis B patients: systematic review with meta-analyses Hepatitis B virus infection Hepatitis B virus infection: understanding its epidemiology, course, and diagnosis Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis Rapid point-of-care first-line screening tests for hepatitis B infection: a meta-analysis of diagnostic accuracy WHO guide to cost-eff ectiveness analysis. Geneva:World Health Organization Methods for economic evaluation project (MEEP): the Gates reference case Hepatitis B vaccination coverage rates among adults in rural China: are economic barriers relevant? Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study Analysis of five quantitative test results of hepatitis B in 5739 pregnant women in Qinhuangdao Investigation and analysis on serum epidemiology of hepatitis B in different years in Jilin Province Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional study The prevalence of hepatitis B infection in central China: An adult population-based serological survey of a large sample size Serological survey of hepatitis B at national disease surveillance sites in Henan Province in 2014 Serological Epidemiology Analysis of the Hepatitis B Virus Infection in Yunnan Province Investigation of Related Knowledge and Behavior of Viral Hepatitis among Food and Public Places Personnel in Changping District of Beijing City Positive Rate of Different Hepatitis B Virus Serological Markers in Peking Union Medical College Hospital,a General Tertiary Hospital in Beijing Detection results of hepatitis B two half-and-half among 4 039 cases of pre-pregnancy eugenics examination couples. Occupation and Health Analysis on Hepatitis B Vaccine Coverage among the Population of 1 ～ 59 Years Old in Shandong Province Community-based epidemiological survey of adult hepatitis B in Chaoyang District Vaccination Progress of Hepatitis B Vaccine and Epidemiology Changes of Carrying Rate of Hepatitis B Surface Antigen by Province in China Seroepidemiology of hepatitis B in healthy population in Tianjin Analysis of Quantitative Test Results of Five Indexes of Hepatitis B for 10499 Different Cases in Qinhuangdao Prevalence pattern of hepatitis B among minority population in Guizhou Province Infection Status Survey of Hepatitis B Virus in Shenyang Citizens Seroepidemiological analysis of viral hepatitis B among healthy people in Heilongjiang Province Analysis on the distribution characteristics of hepatitis B surface antigen antibodies in the population of 0-60 years old in Dalian Seroepidemiological analysis on hepatitis B virus infection among community residents in Shanghai Sampling survey of hepatitis B seroepidemiology among people over 1 year old in Jiangyin City A prevalence and knowledge survey on hepatitis B among population in rural areas in a city of Anhui Province Epidemiological characteristics of hepatitis B infection among people aged 1-29 years in Fujian Province Seroepidemiological survey of adult viral hepatitis B in Henan Province in 2012 Seroepidemiological survey of hepatitis B in couples planning pregnancy in Chongqing in 2013 Analysis of the current status of carrying hepatitis B surface antigen in the population of Ningxia in 2010 Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy The ISPOR CHEERS Task